Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-01-31 (mmm-online.com)
Rx Rundown: Merck, Biogen, Pfizer and more - MM+M - Medical Marketing and Media
Check out this week’s medical marketing news, dealmaking and industry chatter.
Read more
2025-01-11 (biopharmadive.com)
Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets |
Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire.
Read more
2024-11-19 (lalibre.be)
Uncertainty weighs on the stock markets as tension rises with Russia: the BEL20 loses almost 1%
There were only two positive values at the close of the Brussels index. The declines, on the other hand, are numerous.
Read more
2024-09-13 (marketbeat.com)
Biogen (NASDAQ:BIIB) Stock Price Down 2.3%
Biogen (NASDAQ:BIIB) Stock Price Down 2.3%
Read more
2024-09-13 (teleborsa.it)
New York: Depressed day for Biogen
Down session for the American biotechnology company, which shows a decrease of 1.84%. Biogen's one-week trend is weaker than the S&P-500.
Read more
2024-06-12 (reuters.com)
Biogen executive plays down looming competition for its Alzheimer's drug |
Biogen's Alzheimer's drug, Leqembi, will do well in the market whether a competitor comes or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday.
Read more
2022-05-03 (forbes.com)
Biogen CEO Stepping Down After Struggles With Alzheimer’s Drug Aduhelm
The company said it will substantially eliminate the sales infrastructure related to Aduhelm, which is intended to provide savings of $1 billion annually when combined with other cost reductions.
Read more
2019-06-27 (businesswire.com)
Neuroscience Is The Next Oncology: Why Biogen Is Doubling Down - ResearchAndMarkets.com | Business Wire
DUBLIN--(BUSINESS WIRE)--The "Neuroscience Is The Next Oncology: Why Biogen Is Doubling Down" newsletter has been added to ResearchAndMarkets.com's offering.
Read more
2019-05-21 (barrons.com)
The Best and Worst Big Biotech Stocks, According to One Analyst
Credit Suisse’s Evan Seigerman gives a thumbs up to Vertex Pharmaceuticals and a thumbs down to Biogen.
Read more
2016-04-20 (analist.be)
Analysts expect significantly more turnover from biotech underperformer Biogen, but still no dividends | Analyst.be
Over the past 12 months, Biogen shares are down 36 percent - April 20
Read more
2014-03-21 (thestreet.com)
Why Biogen Idec (BIIB) Is Down Today
Biogen Idec (BIIB) dropped on Friday as the biotech sector sagged amid controversy tied to Gilead Sciences' (GILD) hepatitis C drug Sovaldi, which has been priced at $1,000 a day. The drop comes despite news that Health Canada has approved Biogen Idec 's ALPROLIX Coagulation Factor IX( Recombinant),
Read more
(bioprocessintl.com)
Biogen to build $200m NC plant to support gene therapy ambitions Biogen to build $200m NC plant to support gene therapy ambitions
Biogen has laid down plans to build a gene therapy manufacturing at its Research Triangle Park (RTP) manufacturing campus in North Carolina.
Read more